Blue Trust Inc. Has $263,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Blue Trust Inc. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 29.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,336 shares of the medical research company’s stock after acquiring an additional 306 shares during the period. Blue Trust Inc.’s holdings in IQVIA were worth $263,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in shares of IQVIA in the third quarter valued at $28,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. boosted its stake in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. Finally, UMB Bank n.a. boosted its position in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after purchasing an additional 99 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.2 %

IQV stock opened at $201.34 on Monday. The stock’s 50 day simple moving average is $200.41 and its 200 day simple moving average is $220.39. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $36.54 billion, a P/E ratio of 26.42, a price-to-earnings-growth ratio of 2.12 and a beta of 1.48.

Analysts Set New Price Targets

Several equities analysts have recently commented on IQV shares. Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.